摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4-(4-bromothiazol-2-yl)-4-hydroxypiperidine-1-carboxylate | 1313009-82-3

中文名称
——
中文别名
——
英文名称
tert-butyl 4-(4-bromothiazol-2-yl)-4-hydroxypiperidine-1-carboxylate
英文别名
tert-butyl 4-(4-bromo-1,3-thiazol-2-yl)-4-hydroxypiperidine-1-carboxylate
tert-butyl 4-(4-bromothiazol-2-yl)-4-hydroxypiperidine-1-carboxylate化学式
CAS
1313009-82-3
化学式
C13H19BrN2O3S
mdl
——
分子量
363.275
InChiKey
JGTNMIQSBBWYDN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.69
  • 拓扑面积:
    90.9
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • ALXR AGONIST COMPOUND
    申请人:ONO PHARMACEUTICAL CO., LTD.
    公开号:US20160145249A1
    公开(公告)日:2016-05-26
    The present invention provides a compound having ALXR agonist activity. Specifically, the invention provides a compound having ALXR agonist activity represented by general formula (I) wherein all the symbols are as defined in the specification, a salt thereof, a solvate thereof, or a prodrug thereof as well as an agent containing the same as an active ingredient for preventing and/or treating an ALXR-associated disease, such as an inflammatory bowel disease, an autoimmune disease, a chronic inflammatory disease, asthma, pulmonary fibrosis, atopic dermatitis, ischemia-reperfusion injury, myocardial infarction, or Alzheimer's disease.
    本发明提供了一种具有ALXR激动剂活性的化合物。具体来说,该发明提供了一种具有ALXR激动剂活性的化合物,其由通式(I)表示,其中所有符号如规范中定义,其盐、溶剂合物或前药,以及含有该化合物作为活性成分的药剂,用于预防和/或治疗与ALXR相关的疾病,如炎症性肠病、自身免疫疾病、慢性炎症性疾病、哮喘、肺纤维化、特应性皮炎、缺血再灌注损伤、心肌梗死或阿尔茨海默病。
  • Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
    申请人:Tsuchiya Tomoki
    公开号:US20120122928A1
    公开(公告)日:2012-05-17
    Heteroarylpiperidine and -piperazine derivatives of the formula (I) in which the symbols A, X, Y, L 1 , L 2 , G, Q, p, R 1 , R 2 and R 10 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi, and processes for preparing the compounds of the formula (I).
    异芳基哌啶和哌嗪的衍生物的化学式为(I),其中符号A、X、Y、L1、L2、G、Q、p、R1、R2和R10的定义如描述中所述,以及化合物的盐、金属络合物和N-氧化物,以及其用于控制植物病原真菌的用途,以及制备化合物的过程。
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    申请人:Forma Therapeutics, Inc.
    公开号:US20150232445A1
    公开(公告)日:2015-08-20
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R 1 , R 2 , R 5 , and R 8 are as described herein.
    本发明涉及抑制溴和额外末端(BET)溴域的抑制剂,其可用于治疗癌症、炎症性疾病、糖尿病和肥胖症,其化学式为I:其中W、X、Y、Z、R1、R2、R5和R8如本文所述。
  • Tetrahydroquinoline compositions as BET bromodomain inhibitors
    申请人:Forma Therapeutics, Inc.
    公开号:US09388161B2
    公开(公告)日:2016-07-12
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    本发明涉及用于治疗癌症、炎症性疾病、糖尿病和肥胖症的溴和额外末端(BET)溴域抑制剂,具有公式I:其中W、X、Y、Z、R1、R2、R5和R8如本文所述。
  • TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS
    申请人:Forma Therapeutics, Inc.
    公开号:EP3799872A1
    公开(公告)日:2021-04-07
    The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    本发明涉及可用于治疗癌症、炎症性疾病、糖尿病和肥胖症的具有式 I 的溴外末端 (BET) 溴odomains 抑制剂: 其中 W、X、Y、Z、R1、R2、R5 和 R8 如本文所述。
查看更多